Purpose: 150-kDa oxygen-regulated protein (ORP150), a member of heatshock protein family located in endoplasmic reticulum (ER), has a critical role in secretion of vascular endothelial growth factor (VEGF). We investigated expression levels of ORP150 and correlated these levels with VEGF and total vitreous antioxidant capacity (TAC) in proliferative diabetic retinopathy (PDR). We also examined expression of ORP150 in retinas of diabetic rats and in human retinal microvascular endothelial cells (HRMEC). Methods: Vitreous samples from 40 PDR and 20 non-diabetic patients, epiretinal membranes from 14 patients with PDR, retinas of rats and HRMEC were studied by enzyme-linked immunosorbent assay, immunohistochemistry and Western blot analysis. Results: We showed a significant increase in expression of VEGF and ORP150 in vitreous samples from PDR patients compared with controls (p < 0.0001 for both comparisons).Totalvitreousantioxidantcapacity(TAC)levelsweresignificantlylowerin patients with PDR than those in controls (p < 0.0001). Vascular endothelial growth factor (VEGF) and ORP150 levels in PDR with active neovascularization were significantly higher than that in inactive PDR (p = 0.016; p = 0.011, respectively). A significant positive correlation was observed between levels of ORP150 and levels of VEGF (r = 0.42; p = 0.001). In epiretinal membranes, ORP150 was expressed in vascular endothelial cells and stromal cells. We also demonstrated colocalization of the nuclear cell proliferation marker Ki67 and ORP150 in endothelial cells of pathologic new blood vessels. 150-kDa oxygen-regulated protein (ORP150) levels were significantly increased in rat retinas after induction of diabetes. Vascular endothelial growth factor (VEGF) and the pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a) induced upregulation of ORP150 in HRMEC. Conclusion: These results suggest a role for ORP150 in PDR angiogenesis.
Introduction
Ischaemia-induced retinal neovascularization is a common pathway in PDR and often leads to catastrophic loss of vision due to vitreous haemorrhage and/or traction retinal detachment. In PDR, hypoxia seems to be a critical stimulus for neovascularization by upregulating the production of angiogenic stimulators. This angiogenic switch leads to the formation of new blood vessels from preexisting vascular structures (Hanahan & Folkman 1996; Carmeliet 2003) . Among the factors that mediate angiogenesis in PDR, VEGF has been the subject of extensive research because of its selective mitogenic effect on endothelial cells, promoting retinal neovascularization and vascular leakage (Spranger & Pfeiffer 2001; Miller et al. 2013) . As a part of the adaptive responses that induce angiogenesis, hypoxia-mediated induction of VEGF has been demonstrated in retinal cells (Shima et al. 1995; Stone et al. 1995; Mammadzada et al. 2016) . Regulation of angiogenesis has emerged as a potential therapeutic strategy to arrest the progression of PDR angiogenesis (Salam et al. 2011) . To aid the progress of anti-angiogenic therapies, a more comprehensive understanding of the molecules that regulate the processing and secretion of VEGF in PDR is of value to identify additional therapeutic targets.
The 150-kDa oxygen-regulated protein (ORP150) is a member of the heatshock protein family located in the ER that functions as a molecular chaperone in the folding and transport of newly synthesized proteins. 150-kDa oxygenregulated protein (ORP150) was initially characterized based on its selective expression in cultured rat astrocytes subjected to hypoxic stress . Since then, ORP150 has been reported to be induced by hypoxic stress in a wide range of cells (Tsukamoto et al. 1996; Ozawa et al. 2001a,b; Kim et al. 2012 ). In addition, ORP150 has been reported to be induced by oxidative stress (Goswami et al. 2003; Ozawa et al. 2005) . Expression of ORP150 has been shown to provide anti-apoptotic signals and is required for cells to survive prolonged hypoxia (Ozawa et al. 1999; Cechowska-Pasko et al. 2006 ). In the central nervous system, ORP150 overexpression was found to protect neurons from hypoxia/ischaemia by suppression of apoptosis (Tamatani et al. 2001) . Upregulated expression of inducible ORP150 was demonstrated in a range of pathologic situations, such as ischaemic brain Matsushita et al. 1998) , ischaemic retina (Kim et al. 2012) , atherosclerotic plaques (Tsukamoto et al. 1996) and malignant tumours Ozawa et al. 2001a,b; Miyagi et al. 2002; Stojadinovic et al. 2006 ). In addition, overexpression of ORP150 was demonstrated during wound healing (Ozawa et al. 2001a) . These data suggest that ORP150 may contribute in a fundamental way to the cellular response to environmental stress. 150-kDa oxygenregulated protein (ORP150) plays a critical role in the post-translational regulation of secretory proteins, such as VEGF (Ozawa et al. 2001a,b) . Optimal function of ORP150 is essential for secretion of mature VEGF. Increased levels of ORP150 promotes VEGF processing with subsequent transport from ER to the Golgi compartment, followed by export out of the cell (Ozawa et al. 2001a,b) .
Given the critical roles of ORP150 in the processing and secretion of VEGF, we investigated the hypothesis that ORP150 may be involved in the pathogenesis of PDR. To test this hypothesis, we investigated the expression of ORP150 in the vitreous fluid and epiretinal fibrovascular membranes from patients with PDR and correlated ORP150 levels with the levels of the angiogenic factor VEGF and the TAC, a marker of the efficiency of antioxidant defences. To corroborate a functional link between ORP150 and diabetes, we investigated the expression of ORP150 in the retinas of diabetic rats. In addition, we investigated the expression of ORP150 in HRMEC following exposure to hydrogen peroxide (H 2 O 2 )-induced oxidative stress, to the pro-inflammatory cytokines interleukin-6 TNF-a and high-mobility group box-1 (HMGB1) and VEGF proteins.
Materials and Methods

Vitreous samples and epiretinal membranes specimens
Undiluted vitreous fluid samples (0.3-0.6 ml) were obtained from 40 patients with PDR during pars plana vitrectomy. The indications for vitrectomy were tractional retinal detachment, and/or non-clearing vitreous haemorrhage. The severity of retinal neovascular activity was graded clinically at the time of vitrectomy using previously published criteria (Aiello et al. 1994) . Neovascularization was considered active if there were visible perfused new vessels on the retina or optic disc present within epiretinal membranes. Neovascularization was considered inactive (involuted) if only non-vascularized, white fibrotic epiretinal membranes were present. Active PDR was present in 20 patients, and inactive PDR was present in 20 patients. The control group consisted of 20 patients who had undergone vitrectomy for the treatment of rhegmatogenous retinal detachment with no proliferative vitreoretinopathy (PVR). Controls were free from systemic disease. Vitreous samples were collected undiluted by manual suction into a syringe through the aspiration line of vitrectomy, before opening the infusion line. The samples were centrifuged (700 g for 10 min, 4°C), and the supernatants were aliquoted and frozen at À80°C until assay. Epiretinal fibrovascular membranes were obtained from 14 patients with PDR during pars plana vitrectomy for the repair of tractional retinal detachment. For comparison, fibrocellular epiretinal membranes were obtained from 10 patients without diabetes undergoing vitreoretinal surgery for the treatment of retinal detachment complicated by PVR. Membranes were fixed for 2 hr in 10% formalin solution and embedded in paraffin.
The study was conducted according to the tenets of the Declaration of Helsinki. All the patients were candidates for vitrectomy as a surgical procedure. All patients signed a preoperative informed written consent and approved the use of the excised epiretinal membranes and vitreous fluid for further analysis and clinical research. The study design and the protocol were approved by the Research Centre and Institutional Review Board of the College of Medicine, King Saud University.
Rat streptozotocin-induced diabetes model
All procedures with animals were performed in accordance with the ARVO statements for the use of animals in ophthalmic and vision research and were approved by the Institutional Animal Care and Use Committee of the College of Pharmacy, King Saud University. Adult male Sprague-Dawley rats, 8-9 weeks of age weighting in the range of 220-250 g, were overnight fasted, and streptozotocin (STZ) (65 mg/kg in 50 mM sodium citrate buffer, pH 4.5; Sigma, St. Louis, MO, USA) was injected intraperitoneally as a single bolus. Equal volumes of citrate buffer were injected in non-diabetic control animals. Measurement of blood glucose concentrations and body weights were started 3 days after injection of STZ. Diabetes was confirmed by assaying the glucose concentration in blood taken from the tail vein. Rats with glucose levels >250 mg/dl were categorized as diabetic. After 4 weeks of diabetes, animals were anesthetized by intraperitoneal injection of an overdose of chloral hydrate and killed by decapitation. Retinas were dissected, flash frozen and stored at À70°C until use. Similarly, retinas were obtained from age-matched non-diabetic control rats. (10 lM or 40 lM) (Scharlau, Sentmenat, Spain) for 6 hr. The used concentrations of these agonists were selected based on previous studies. (Ozawa et al. 2005; Abu El-Asrar et al. 2015 , 2017a Yun et al. 2017) . Cells were then harvested and lysed in RIPA lysis buffer (sc-24948; Santa Cruz Biotechnology, Dallas, TX, USA) for Western blot analysis.
Enzyme-linked immunosorbent assays
An enzyme-linked immunosorbent assay (ELISA) kit for human HYOU1/ORP150 (Cat No: LS-F6532) was purchased from LifeSpan Biosciences, Seattle, WA, USA. An ELISA kit for human VEGF (Cat No: SVE00) was purchased from R&D Systems. The minimum detection limits for HYOU1/ORP150 and VEGF ELISA kits were 156 ng/ml and 9 pg/ml, respectively. The ELISA plate readings were taken using a Stat Fax-4200 microplate reader from Awareness Technology, Inc., Palm City, FL, USA. The quantification of human HYOU1/ORP150 and VEGF in vitreous fluid was determined using ELISA Kits according to the manufacturer's instructions.
Measurement of total antioxidant capacity in the vitreous fluid
Total antioxidant status in the vitreous fluid was analysed with a commercially available TAC Assay Kit (Cat No: STA-360) purchased from Cell Biolabs' OxiSelect TM , San Diego, CA, USA. The kit was used according to the manufacturer's instructions.
Western blot analysis
Retinas from diabetic and control rats were homogenized in Western blot lysis buffer (30 mM Tris-HCl; pH 7.5, 5 mM EDTA, 1% Triton-X-100, 250 mM sucrose, 1 mM Sodium vanadate and protease inhibitor cocktail). The protease inhibitor used was 'Complete without EDTA' (Roche, Mannheim, Germany). The homogenates were centrifuged at 14 000 g for 15 min at 4°C, and the supernatants were used for protein estimation and further analysis. Human retinal microvascular endothelial cells (HRMECs) were lysed after harvest with RIPA buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Nonidet P40 (NP40)], 0.5% Sodium deoxycholate, 0.1% SDS and protease inhibitor 'Complete without EDTA'. Whole cell extracts from the treated groups were centrifuged at 12 000 g for 10 min at 4°C. The supernatants were collected, and protein concentrations were measured with the use of DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of extracted protein (50 lg) were subjected to SDS-polyacrylamide gel (SDS-PAGE) electrophoresis in 8-10% gels and transferred onto nitrocellulose membranes (Bio-Rad Laboratories). To determine the expression levels of ORP150 in the vitreous samples, equal volumes (15 ll) of vitreous samples were boiled in Laemmli's sample buffer (1:1, v/v) under reducing conditions for 10 min and analysed. Non-specific binding sites were blocked (1.5 hr, room temperature) with 5% non-fat milk made in Tris-buffered saline containing 0.1% Tween-20 (TBS-T). Blots were then incubated at 4°C overnight with anti-ORP150 antibody (1:1000; ab134944, Abcam). Three TBS-T washings (5 min each) were performed prior to secondary antibody treatment at room temperature for 1 hr. To investigate the colocalization of ORP150 and the nuclear cell proliferation marker Ki67, sequential double immunohistochemistry was performed. The sections were incubated with the first primary antibody (mouse monoclonal anti-Ki67; ready-to-use; clone MIB-1; Agilent Technologies, Santa Clara, CA, USA) and subsequently treated with peroxidase conjugated secondary antibody. The immunor-eactivity was visualized with 3, 3 0 -diaminobenzidine tetrahydrochloride. Incubation of the second primary antibody (anti-ORP150) was followed by treatment with alkaline phosphataseconjugated secondary antibody, and immunoreactivity was visualized with fast red. No counterstain was applied. Omission or substitution of the primary antibody with an irrelevant antibody from the same species and staining with chromogen alone were used as negative control reactions.
Statistical analysis
Data were presented as the mean AE standard error of mean (SEM). The Kruskal-Wallis test was used to compare means among active patients with PDR, inactive PDR patients and nondiabetic control patients. The nonparametric Mann-Whitney test was used to compare means from two independent groups. Spearman correlation coefficients were computed to investigate correlations between variables. A p-value <0.05 indicated statistical significance. SPSS version 22.0 for Windows (IBM Inc., Chicago, IL, USA) was used for statistical analysis.
Results
ELISA levels of VEGF, ORP150 and TAC in vitreous samples
Vascular endothelial growth factor (VEGF) was detected in 11 of 20 (55%) vitreous samples from non-diabetic control patients, and in 35 of 40 (87.5%) vitreous samples from patients with PDR. The mean VEGF levels in vitreous samples from patients with PDR were significantly higher than the mean levels in non-diabetic control patients (p < 0.0001; Mann-Whitney test) ( Table 1) . 150-kDa oxygen-regulated protein (ORP150) was detected in 17 of 20 (85%) vitreous samples from non-diabetic control patients, and in 37 of 40 (92.5%) vitreous samples from patients with PDR. The mean ORP150 levels in patients with PDR were significantly higher than the mean levels in non-diabetic control patients (p < 0.0001; Mann-Whitney test) ( Table 1 ). The mean TAC levels in vitreous samples from PDR patients were significantly lower than the mean levels in non-diabetic control patients (p < 0.0001; Mann-Whitney test) ( Table 1) .
Relationship between levels of VEGF, ORP150 and TAC and activity of PDR Comparisons of mean levels of VEGF, ORP150 and TAC among active PDR patients, inactive PDR patients and nondiabetic control patients were conducted with the Kruskal-Wallis test, and the results are shown in Table 1 . Mean levels differed significantly between the three groups for VEGF (p < 0.0001), ORP150 (p < 0.0001) and TAC (p = 0.019). Pairwise comparisons (Mann-Whitney test) indicated that mean VEGF levels were significantly higher in patients with active PDR than in inactive PDR patients (p = 0.016) and control patients (p < 0.0001). In addition, mean VEGF levels in patients with inactive PDR were significantly higher than mean levels in control patients (p < 0.0001). Mean ORP150 levels were significantly higher in patients with active PDR than in inactive PDR patients (p = 0.022) and control patients (p < 0.0001). For TAC, mean levels were significantly lower in patients with inactive PDR than that in non-diabetic patients (p = 0.008).
Correlations
A significant positive correlation was found between vitreous fluid levels of ORP150 and levels of VEGF (r = 0.42; p = 0.001) (Fig. 1) . In contrast, the correlations between levels of ORP150 and levels of TAC (r = À0.08; p = 0.56) and between levels of VEGF and levels of TAC (r = À0.21; p = 0.1) were not significant.
Western blot analysis of vitreous samples
With the use of Western blot analysis of equal volumes of vitreous fluid, we confirmed that ORP150 was present in vitreous samples and that ORP150 expression was enhanced in PDR. ORP150 migrated at the position of its expected molecular weight (150 kDa) and, indeed, densitometric analysis of the 150 kDa band demonstrated a significant increase in ORP150 expression in samples from PDR patients (n = 12) compared with samples from non-diabetic control patients (n = 12). (Fig. 2) .
Immunohistochemical analysis of epiretinal membranes from patients with PDR
To identify the cellular source of vitreous fluid ORP150, epiretinal fibrovascular membranes from patients with PDR were studied by immunohistochemical analysis. No staining was observed in the negative control slides. All membranes showed pathologic new blood vessels, positive for the endothelial cell marker CD31 (Fig. 3A) . Immunoreactivity for ORP150 was present in all membranes and was noted in vascular endothelial cells and stromal cells (Fig. 3B,C) . In comparison, there was no immunoreactivity for ORP150 in epiretinal membranes from patients with PVR (Fig. 3D) . Double immunohistochemistry demonstrated that endothelial cells of pathologic new blood vessels expressing ORP150 (red) co-expressed the nuclear cell proliferation marker Ki67 (brown) (Fig. 4) .
Effect of diabetes on retinal expression of ORP150
The body weights of the diabetic rats were lower, and their blood glucose levels were more than fourfold higher compared with age-matched normal control rats (171 AE 20 g versus 269 AE 27 g and 487 AE 31 mg/dl versus 107 AE 10 mg/dl, respectively). Western blot analysis of homogenized retinal tissue was in accordance with the thesis that diabetes induced significant upregulation of ORP150 (p = 0.007; MannWhitney test) (Fig. 5) (Fig. 6) . In contrast, treatment of HRMEC with H 2 O 2 and HMGB1 did not affect the expression of ORP150 as compared to untreated control (data not shown).
Discussion
In the present study, we showed for the first time that the inducible ER chaperone ORP150 was significantly upregulated in the vitreous fluid from patients with PDR, and in the retinas of diabetic rats. Our subgroup analysis showed that the vitreous levels of ORP150 were higher in PDR eyes with active neovascularization compared with eyes with quiescent disease. ORP150 was expressed by endothelial cells of pathologic new blood vessels and stromal cells in PDR fibrovascular epiretinal membranes. To corroborate the findings at the cellular level, stimulation with VEGF and the proinflammatory cytokines IL-6 and TNF-a caused upregulation of ROP150 in HRMEC. These findings suggest that the inflammatory ocular microenvironment of patients with PDR may enhance ORP150 expression in endothelial cells of pathologic new blood vessels.
We assume that cell damage during the course of PDR progression leads to release of ORP150 into the vitreous fluid. Similarly, it was reported that ORP150 gains access to the extracellular space, resulting in the production of autoantibodies to ORP150 in the sera of patients with malignant tumours (Ozawa et al. 2001b) , severe atherosclerosis (Tsukamoto et al. 1996) and type I diabetes (Nakatani et al. 2006 ). These findings suggest that ER stress is increased in these pathologic situations and that ORP150 may be a marker of vascular pathology.
Our results are consistent with a previous report on upregulation of retinal ORP150 expression in the mouse model of oxygen-induced retinopathy, a model of blinding ischaemic retinopathy. 150-kDa oxygen-regulated protein (ORP150) expression was colocalized to the retinal neovascular tufts (Kim et al. 2012) . Moreover, knockdown of ORP150 by intravitreal administration of siRNA targeting ORP150 significantly reduced retinal neovascularization (Kim et al. 2012) . Taken together, these findings suggest that upregulation of ORP150 in the ocular microenvironment of patients with PDR might contribute to the initiation and progression of angiogenesis associated with PDR.
A link between tumour growth and increased ORP150 levels was suggested. In these studies, it was suggested that tumour growth and invasiveness were associated with ORP150 expression Ozawa et al. 2001b; Miyagi et al. 2002; Stojadinovic et al. 2006) . Colocalization of ORP150 and VEGF was demonstrated in human malignant tumours (Ozawa et al. 2001b; Miyagi et al. 2002) , and in healing wounds (Ozawa et al. 2001a) , suggesting a role of ORP150 in the promotion of angiogenesis. In addition, a positive correlation between the expression of ORP150 and VEGF secretion was demonstrated in human malignant tumours (Ozawa et al. 2001b; Miyagi et al. 2002) . Several studies demonstrated a critical role for ORP150 in tumour-mediated angiogenesis via processing and secretion of VEGF (Ozawa et al. 2001b; Miyagi et al. 2002) . 150-kDa oxygenregulated protein (ORP150) plays an important role in the secretion of VEGF as a molecular chaperone (Ozawa et al. 2001a,b) . Enhanced expression of ORP150 was associated with increased VEGF secretion and tumour growth promotion. On the other hand, suppression of ORP150 decreased VEGF secretion, reduced angiogenesis and caused tumour regression (Ozawa et al. 2001b; Miyagi et al. 2002) . In human wounds, overexpression of ORP150 increased VEGF expression and accelerated wound closure and angiogenesis, whereas suppression of ORP150 suppressed VEGF expression and delayed the reparative processes (Ozawa et al. 2001a) . Furthermore, downregulation of ORP150 expression in hypoxic macrophages (Ozawa et al. 2001a) and in retinal pigment epithelial cells (Kim et al. 2012 ) decreased the levels of secreted VEGF, resulting in retention of VEGF in the ER.
We detected simultaneous expression of ORP150 and VEGF in the vitreous fluid from patients with PDR. Moreover, a significant positive correlation between the levels of ORP150 and the levels of VEGF was observed. ORP150 was specifically localized in vascular endothelial cells and stromal cells in PDR epiretinal fibrovascular membranes. In previous studies, we demonstrated VEGF localization in vascular endothelial cells and stromal cells in epiretinal membranes from patients with PDR (Abu El-Asrar et al. 2007 ). Our findings are in accordance with previous reports that demonstrated co-expression of ORP150 and VEGF in human malignant tumours (Ozawa et al. 2001b; Miyagi et al. 2002) and in healing wounds (Ozawa et al. 2001a ) and the positive correlation between the expression of ORP150 and VEGF secretion in human malignant tumours (Ozawa et al. 2001b; Miyagi et al. 2002) . The co-expression of ORP150 and VEGF in the ocular microenvironment of patients with PDR suggests a cross-talk between these factors in the pathogenesis of PDR angiogenesis and that the coexpression of these factors is mechanistically interrelated. In addition, we demonstrated the colocalization of the nuclear cell proliferation marker Ki67 and ORP150 in endothelial cells of pathologic new blood vessels that were positive for the endothelial cell marker CD31 in PDR fibrovascular epiretinal membranes. These results are in agreement with a previous report that demonstrated high ORP150 expression in actively growing cells (CechowskaPasko et al. 2005) .
There is evidence to suggest that hyperglycaemia-induced oxidative stress greatly contributes to the pathogenesis of diabetic retinopathy (Kowluru et al. 2015; Mohammad et al. 2015; Behl et al. 2016) . Oxidative stress occurs when the production of reactive oxygen species exceeds the capacity of the cells to detoxify these injurious oxidants with the use of endogenous antioxidant defence systems (Cooper et al. 2002) . Hypoxia is known to elicit excess reactive oxygen species production and thereby alter redox balance (Debevec et al. 2017) . In the present study, we demonstrated that patients with PDR had significantly lower levels of TAC compared with non-diabetic control patients, meaning that their vitreous antioxidant defences were significantly reduced. These results are in agreement with previous reports (Yokoi et al. 2007; Mancino et al. 2011) . We detected no significant correlation between the total vitreous antioxidant status and the vitreous fluid levels of ORP150. In addition, the expression of ORP150 was not affected by H 2 O 2 -induced oxidative stress in HRMEC. Similarly, HMGB1, which is known to mediate upregulation of reactive oxygen species and oxidative stress in diabetic retina (Mohammad et al. 2015) , did not affect the expression of ORP150 in HRMEC. These findings suggest that upregulation of ORP150 in the ocular microenvironment of patients with PDR might not be induced by oxidative stress.
In conclusion, our study provides evidence that the hypoxia-inducible protein ORP150 is upregulated in the ocular microenvironment of patients with PDR. In addition, our findings suggest a role for ORP150 in PDR angiogenesis and thus highlight a novel angiogenic pathway amenable to therapeutic manipulation by modulating the expression of ORP150. Vascular endothelial growth factor in ocular Fig. 6 . Effect of vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF-a) and interleukin-6 (IL-6) on the expression of 150-kDa oxygen-regulated protein (ORP150) in human retinal microvascular endothelial cells. Protein expression of ORP150 in treated and untreated (C) cell lysates was determined by Western blot analysis. Western blots are representative of three independent experiments, each performed in duplicate and bar graphs are representative of all three experiments. Compared to untreated control, the difference between the two means was statistically significant at 5% level of significance (Mann-Whitney test).
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